WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013115559) METHOD FOR PREPARING ALBUMIN NANOPARTICLES CONTAINING POORLY WATER SOLUBLE DRUG THEREIN
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/115559 International Application No.: PCT/KR2013/000752
Publication Date: 08.08.2013 International Filing Date: 30.01.2013
IPC:
A61K 38/38 (2006.01) ,A61K 9/16 (2006.01) ,A61K 47/48 (2006.01) ,A61K 47/30 (2006.01)
Applicants: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY[KR/KR]; Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-746, KR
Inventors: JEONG, Ji Hoon; KR
KIM, Myung Goo; KR
LEE, Min Sang; KR
JANG, Yeon Lim; KR
Agent: SON, Min; Hanol Intellectual Property & Law STX R&D Center, 6th Floor 163, YangJaeCheon-ro, Gangnam-gu Seoul 135-855, KR
Priority Data:
10-2012-000925330.01.2012KR
Title (EN) METHOD FOR PREPARING ALBUMIN NANOPARTICLES CONTAINING POORLY WATER SOLUBLE DRUG THEREIN
(FR) PROCÉDÉ DE PRÉPARATION DE NANOPARTICULES D'ALBUMINE INCORPORANT UN MÉDICAMENT FAIBLEMENT SOLUBLE DANS L'EAU
(KO) 수난용성 약물을 내부에 포함하는 알부민 나노입자 제조방법
Abstract: front page image
(EN) The present invention relates to a method for preparing non-peptidic polymer and albumin assembly nanoparticles containing a poorly water soluble drug therein and capable of mediating in vivo delivery through solubilization and stabilization in an aqueous solution. Particularly, a non-peptidic polymer and albumin assembly and a poorly water soluble drug can be simultaneously dissolved even if using only an organic solvent, and thus the two components are mixed well even if a separate chemical or physical action is not applied. In addition, a method for preparing polyethylene glycol and albumin assembly nanoparticles according to the present invention does not contain a surfactant and a solubilizing agent, and thus does not cause a hypersensitive reaction or a toxic reaction due to the formulation of a poorly water soluble drug and can increase the compliance of a patient. Further, the present invention can also be useful for the stabilization and the like of inorganic nanoparticles for image/diagnosis and of various poorly water soluble drugs.
(FR) La présente invention concerne un procédé de préparation de nanoparticules d'assemblage de polymère non peptidique et d'albumine incorporant un médicament faiblement soluble dans l'eau et pouvant servir d'intermédiaire à une délivrance in vivo par une solubilisation et une stabilisation dans une solution aqueuse. Plus particulièrement, selon l'invention, un assemblage de polymère non peptidique et d'albumine et un médicament faiblement soluble dans l'eau peuvent être dissous simultanément même si l'on utilise un seul solvant organique et, ainsi, les deux composants sont bien mélangés même sans application d'une action chimique ou physique distincte. De plus, un procédé de préparation de nanoparticules d'assemblage de polyéthylène glycol et d'albumine selon la présente invention ne contient pas de tensioactif ni d'agent solubilisant et ne provoque donc pas de réaction d'hypersensibilité ou de réaction toxique liées à la formule d'un médicament faiblement soluble dans l'eau et peut augmenter la complaisance d'un patient. En outre, la présente invention peut également être utile pour la stabilisation, et analogue, de nanoparticules inorganiques à des fins d'imagerie/diagnostic et de divers médicaments faiblement solubles dans l'eau.
(KO) 본 발명은 수용액상에서의 가용화 및 안정화를 통해 생체 내 전달을 매개할 수 있는 수난용성 약물을 내부에 포함하는 비펩타이드성 중합체와 알부민 회합체 나노입자 제조방법에 관한 것으로, 특히 유기용매만을 사용하더라도 비펩타이드성 중합체와 알부민 회합체 및 수난용성 약물의 동시 용해가 가능하므로 별도의 화학적 또는 물리적인 작용을 가하지 않더라도 두 성분의 혼합이 잘 이루어지게 되는 특징이 있다. 또한, 본 발명에 따른 폴리에틸렌글리콜과 알부민 회합체 나노입자 제조방법은, 계면활성제, 가용화제를 포함하지 않으므로, 수난용성 약물의 제제화에 의한 과민반응 또는 독성반응을 일으키지 않는 동시에 환자의 순응도를 높일 수 있는 장점이 있다. 또한 다양한 수난용성 약물 뿐만 아니라, 영상/진단용 무기나노입자의 안정화 등에도 유용하게 사용될 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)